• Publications
  • Influence
Immunogene Therapy of Recurrent Glioblastoma Multiforme with a Liposomally Encapsulated Replication-Incompetent Semliki Forest Virus Vector Carrying the Human Interleukin-12 Gene – A Phase I/II
Glioblastoma multiforme (GBM) is an incurable brain tumor resistant to standard treatment modalities such as surgery, radiation, and chemotherapy. Since recurrent GBM tends to develop predominantlyExpand
  • 67
  • 4
Expression of soluble guanylyl cyclase
Purified soluble guanylyl cyclase consists of two subunits (70 and 73 kDa) whose primary structures were recently determined. The availability of cDNA clones coding for either subunit allowed toExpand
  • 156
  • 3
A dual function fusion protein of Herpes simplex virus type 1 thymidine kinase and firefly luciferase for noninvasive in vivo imaging of gene therapy in malignant glioma
BackgroundSuicide gene therapy employing the prodrug activating system Herpes simplex virus type 1 thymidine kinase (HSV-TK)/ ganciclovir (GCV) has proven to be effective in killing experimentalExpand
  • 32
  • 1
Minichromosome maintenance protein 3 elicits a cancer-restricted immune response in patients with brain malignancies and is a strong independent predictor of survival in patients with anaplastic
PURPOSE The identification of new molecular markers in astrocytic tumors may help to understand the biology of these tumors in more detail. Informative tumor markers may represent prognostic factorsExpand
  • 32
  • 1
  • PDF
Intracellular localization of Herpes simplex virus type 1 thymidine kinase fused to different fluorescent proteins depends on choice of fluorescent tag
Gene therapy employing the suicide gene/prodrug activating system Herpes simplex virus type 1 thymidine kinase (HSV‐TK)/ganciclovir (GCV) is effective in killing malignant tumor cells. Labeling ofExpand
  • 27
  • 1
Novel therapies for malignant gliomas: a local affair?
Advances in medical and surgical treatments in the last few decades have resulted in quantum leaps in the overall survival of patients with malignant disease outside the central nervous system,Expand
  • 22
  • 1
Immunogene Therapy of Recurrent Glioblastoma Multiforme with a Liposomally Encapsulated Replication-Incompetent Semliki Forest Virus Vector Carrying the Human Interleukin-12 gene – a phase I/II
Glioblastoma multiforme (GBM) is an incurable brain tumor resistant to standard treatment modalities such as surgery, radiation, and chemotherapy. Since recurrent GBM tends to develop predominantlyExpand
  • 61
Bioluminescence imaging in vivo – application to cancer research
Molecular events promoting tumourigenesis and anticancer therapeutic strategies have been intensively studied in tumour cell culture models. In the past few years, non-invasive bioluminescenceExpand
  • 50
Clinical studies with targeted toxins in malignant glioma.
Targeted toxins represent a new class of agents with high specificity for tumor cells. Toxins in current clinical use for the treatment of brain tumors are mostly recombinant polypeptides consistingExpand
  • 30
Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors.
Survivin is a member of the inhibitor of apoptosis protein (IAP) family and is frequently expressed in cancers, including meningiomas and gliomas. Survivin may be associated with tumor progressionExpand
  • 22
  • PDF